secwatch.observer — SEC 8-K summary
======================================

Issuer:     Centessa Pharmaceuticals plc (CNTA)
CIK:        0001847903
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001847903-24-000165
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Centessa discontinues SerpinPC, launches ORX750 Phase 2a, Q3 net loss $42.6M
----------------------------------------------------------------------------

- Additional interim Phase 1 data for ORX750 in sleep-deprived volunteers showed statistically significant increase in wakefulness at all doses with favorable safety; Phase 2a initiated in NT1, NT2, IH.
- Discontinued SerpinPC development after interim analysis; net savings of ~$200M reallocated to OX2R agonist franchise.
- Cash $518.4M as of Sept 30, 2024; expected to fund operations into mid-2027.
- Completed upsized public offering in Sept 2024 resulting in net proceeds of ~$242.7M.
- Advancing ORX142 and ORX489 in IND-enabling studies; clinical data expected in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847903/000184790324000165/0001847903-24-000165-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847903/000184790324000165/cnta-20241112.htm
  HTML page:      https://secwatch.observer/filing/0001847903-24-000165

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer